https://www.appliedxl.com/news/ono-ripretinib-gist-enrollment-nct07618377 Biopharma News en 2026-07-20T15:16:54.071Z Ono opens Japan enrollment for ripretinib in 4th-line GIST https://www.appliedxl.com/news/taibidi-tpd3310-solid-tumors-trial-start-nct07368127 Biopharma News en 2026-07-20T15:16:32.416Z Taibidi opens dosing in first-in-human trial of c-MET drug TPD3310 https://www.appliedxl.com/news/tj-tj037130-solid-tumors-nct07715747 Biopharma News en 2026-07-20T15:16:30.881Z TJ Biopharma registers Phase 1 trial of CLDN6/4-1BB drug TJ037130 https://www.appliedxl.com/news/tricision-survivin-dc-glioblastoma-phase2-nct07715097 Biopharma News en 2026-07-20T15:16:09.242Z Tricision advances survivin-targeted DC therapy into Phase 2 glioblastoma trial https://www.appliedxl.com/news/chongqing-precision-picx-myeloma-trial-nct07715630 Biopharma News en 2026-07-20T15:16:01.592Z Chongqing Precision Biotech starts small in vivo CAR-T trial in myeloma https://www.appliedxl.com/news/suncadia-shr-1501-bladder-cancer-recruiting-nct07424287 Biopharma News en 2026-07-20T15:15:53.614Z Suncadia opens enrollment for SHR-1501 in BCG-unresponsive bladder cancer https://www.appliedxl.com/news/inventisbio-d-2570-hepatic-impairment-nct07715149 Biopharma News en 2026-07-20T15:15:34.374Z InventisBio opens Phase 1 liver-function PK study of D-2570 in China https://www.appliedxl.com/news/hengrui-hrs-9821-copd-phase1-nct07567872 Biopharma News en 2026-07-20T15:15:26.014Z Hengrui opens dosing in third Phase 1 trial of inhaled COPD drug HRS-9821 https://www.appliedxl.com/news/gene-key-gkl-006-hcc-phase1-nct07713290 Biopharma News en 2026-07-20T15:15:11.855Z Gene Key advances GKL-006 HCC trial toward November safety readout https://www.appliedxl.com/news/lilly-loxo-783-breast-cancer-recruiting-nct05307705 Biopharma News en 2026-07-20T15:05:50.634Z Lilly's LOXO-783 breast cancer trial reopens enrollment after two-year pause https://www.appliedxl.com/news/treeline-tln-499-solid-tumors-phase1-nct07713732 Biopharma News en 2026-07-20T15:05:27.332Z Treeline Biosciences opens Phase 1 study of TLN-499 in relapsed tumors https://www.appliedxl.com/news/epicrispr-epi-321-fshd-timing-nct06907875 Biopharma News en 2026-07-20T15:05:14.808Z Epicrispr's EPI-321 FSHD readout pushed to July 2027 as trial closes enrollment https://www.appliedxl.com/news/united-bio-technology-ubt38006-phase1-nct07630233 Biopharma News en 2026-07-20T15:05:05.855Z United Bio-Technology's UBT38006 heads toward first Phase 1 data in October https://www.appliedxl.com/news/inventisbio-d-2570-renal-impairment-pk-nct07715175 Biopharma News en 2026-07-20T15:05:01.134Z InventisBio opens Phase 1 renal-impairment PK study of D-2570 in China https://www.appliedxl.com/news/upstream-bio-verekitug-copd-readout-nct06981078 Biopharma News en 2026-07-20T14:55:46.113Z Upstream Bio pulls in COPD readout for verekitug by six months https://www.appliedxl.com/news/precision-io-epione-2026-data-nct07325578 Biopharma News en 2026-07-20T13:15:19.206Z Precision IO presents Epione robotic MSK ablation data at SRS meeting https://www.appliedxl.com/news/prolocor-pfcg-test-2026-readout-nct05175261 Biopharma News en 2026-07-20T13:34:49.542Z Prolocor biomarker links high pFCG to repeat heart attacks in 765-patient study https://www.appliedxl.com/news/actinogen-xanamem-emestedastat-readout-nct05657691-0c7b84 Biopharma News en 2026-07-20T13:25:25.840Z Xanamem misses cognition goal in depression trial, eases mood symptoms https://www.appliedxl.com/news/kolon-tissuegene-tg-c-2026-readout-nct03291470 Biopharma News en 2026-07-20T12:14:56.969Z Kolon TissueGene's TG-C fails first Phase 3 knee osteoarthritis trial https://www.appliedxl.com/news/treeline-tln-121-2026-readout-nct07082803 Biopharma News en 2026-07-20T11:45:05.164Z Treeline's BCL6 degrader TLN-121 posts 84% response rate in lymphoma https://www.appliedxl.com/news/nouscom-nous-209-2026-readout-nct05078866 Biopharma News en 2026-07-20T11:15:07.080Z Nouscom's NOUS-209 shows durable T-cell response, no new polyps at 1 year https://www.appliedxl.com/news/firsekibart-bioequivalence-formulation-study Biopharma News en 2026-07-20T19:34:39.188Z Firsekibart's solution formulation matches lyophilized version on bioequivalence https://www.appliedxl.com/news/adc-zynlonta-hepatic-impairment-terminated-nct05660395 Biopharma News en 2026-07-20T14:45:29.648Z ADC Therapeutics halts hepatic-impairment PK study of Zynlonta at 5 patients https://www.appliedxl.com/news/lilly-orforglipron-japan-obesity-readout-nct05931380 Biopharma News en 2026-07-20T15:06:59.018Z Lilly's orforglipron hits weight-loss goal in Japanese Phase 3 trial https://www.appliedxl.com/news/corestemchemon-neuronata-r-lenzumestrocel-2026-readout-nct04745299 Biopharma News en 2026-07-19T23:15:14.186Z CorestemChemon's ALS stem cell therapy missed its Phase 3 primary in the full population https://www.appliedxl.com/news/jmkx003002-phase1-nhe3-inhibitor Biopharma News en 2026-07-20T20:15:00.736Z Phase 1 trial shows NHE3 blocker JMKX003002 raises stool sodium excretion https://www.appliedxl.com/news/hrs-7535-diabetic-kidney-disease-readout-nct06415214 Biopharma News en 2026-07-19T19:15:24.510Z HRS-7535 cut albuminuria 32% versus placebo in diabetic kidney disease trial https://www.appliedxl.com/news/sglt2-inhibitors-post-mi-meta-analysis Biopharma News en 2026-07-19T19:24:45.213Z SGLT2 inhibitors cut heart failure hospitalization after MI without diabetes https://www.appliedxl.com/news/tegoprazan-h-pylori-non-inferiority Biopharma News en 2026-07-19T19:44:50.146Z Tegoprazan dual therapy misses non-inferiority mark against bismuth quadruple therapy for H. pylori https://www.appliedxl.com/news/regenxbio-surabgene-lomparvovec-sura-vec-abbv-rgx-314-nct03066258 Biopharma News en 2026-07-19T09:05:49.913Z REGENXBIO's sura-vec holds vision gains through 5 years in a 42-patient wet AMD cohort https://www.appliedxl.com/news/romosozumab-osteogenesis-imperfecta-data Biopharma News en 2026-07-19T19:54:50.029Z Romosozumab lifts spinal bone density in osteogenesis imperfecta but not the hip